Major Drug Class Overview

Drug Class	Preferred Alternatives	Non-Preferred Drugs
ANALGESICS – Hyaluronan Injections for Knee Osteoarthritis	EUFLEXXA, SYNVISC, SYNVISC ONE	DUROLANE, GEL-ONE, GELSYN-3, GENVISC, HYALGAN, HYMOVIS, MONOVISC, ORTHOVISC, SUPARTZ FX, SYNOJOYNT, TRILURON, TRIVISC, VISCO-3
ANALGESICS – Opioid Withdrawal	buprenorphine sublingual, buprenorphine-naloxone sublingual, film	BRIXADI*, SUBLOCADE, SUBOXONE, ZUBSOLV
ANALGESICS – Pain Relief	NUCYNTA ER, XTAMPZA ER, acetaminophen-codeine, buprenorphine (patches, injection), fentanyl, hydrocodone-acetaminophen, hydrocodone, hydromorphone, morphine sulfate, oxycodone, oxycodone-acetaminophen, oxymorphone, tapentadol, tapentadol ER, tramadol	BELBUCA, DEMEROL, DSUVIA, JOURNAVX, NUCYNTA, OXYCONTIN, SEGLENTIS
ANTI-COAGULANTS	BRILINTA, ELIQUIS, XARELTO, clopidogrel, dabigatran, enoxaparin, prasugrel, rivaroxaban 2.5mg, ticagrelor, warfarin	PRADAXA ORAL PELLETS, SAVAYSA, YOSPRALA, ZONTIVITY
ANTI-CONVULSANTS (ANTI-SEIZURES)	APTIOM, DIASTAT PEDIATRIC, DILANTIN, EPIDIOLEX*, brivaracetam, carbamazepine, clobazam, clonazepam, divalproex sodium, eslicarbazepine, ethosuximide, felbamate, gabapentin, lacosamide, lamotrigine, levetiracetam, methsuximide, oxcarbazepine, perampanel, phenytoin, pregabalin, primidone, rufinamide, subvenite, tiagabine, topiramate, topiramate ER, valproic acid, vigabatrin*, zonisamide	BRIVIACT, DIACOMIT, ELEPSIA XR, FANATREX FUSEPAQ, FINTEPLA*, FYCOMPA, LIBERVANT, MOTPOLY XR, NAYZILAM, SPRITAM, SYMPAZAN, VALTOCO, VIGAFYDE*, XCOPRI, ZONISADE, ZTALMY*

The list is not all-inclusive and does not guarantee coverage. Please refer to your benefit plan documents provided by your employer or plan sponsor for benefit coverage and restrictions. This list is revised periodically and is subject to change without notice. Medications may be subject to prior authorization, step therapy requirements and quantity limits.

* = Specialty Drug (Tier 4)
lowercase = Generics; UPPERCASE = Brands
Preferred Alternatives = Generics (Tier 1) and Preferred Brands (Tier 2)
Non-Preferred Drugs = Non-Preferred Brands (Tier 3)

Major Drug Class Overview

Drug Class	Preferred Alternatives	Non-Preferred Drugs
ANTI-DEPRESSANTS	ZURZUVAE (used for PPD), amitriptyline, bupropion, citalopram, desvenlafaxine succinate ER, doxepin, duloxetine, escitalopram, fluoxetine (oral solution, caps, tabs), fluvoxamine, mirtazapine, paroxetine, paroxetine ER, sertraline (oral solution, tabs, caps), trazodone, venlafaxine, vilazodone	APLENZIN, AUVELITY, DRIZALMA SPRINKLE, EMSAM, EXXUA, FETZIMA, MARPLAN, RALDESY, SPRAVATO*, TRINTELLIX
ANTI-HYPERTENSIVES	amlodipine, chlorthalidone, isosorbide dinitrate/hydralazine, hydrochlorothiazide, lisinopril, losartan, nebivolol, spironolactone, valsartan	EDARBI, EDARBYCLOR, INDERAL XL, INNOPRAN XL, NYMALIZE, PRESTALIA, QBRELIS, THALITONE, TRYVIO*, VECAMYL*
ANTI-PSYCHOTICS – Non-Injectables	REXULTI, VRAYLAR, aripiprazole (oral solution, disintegrating tab, tab), asenapine sublingual, fluphenazine (oral solution, elixir, tabs), haloperidol, haloperidol lactate oral solution, lithium (oral solution, caps, tabs), lurasidone, olanzapine (disintegrating tab, tabs), paliperidone ER, quetiapine, risperidone (disintegrating tab, oral solution, tabs), ziprasidone	ABILIFY MYCITE, ADASUVE, BYSANTI, CAPLYTA, COBENFY, EQUETRO, FANAPT, NUPLAZID*, OPIPZA, SECUADO
ANTI-PSYCHOTICS - Injectables	fluphenazine decanoate, haloperidol decanoate, olanzapine, risperidone microsphere ER, ziprasidone mesylate	ABILIFY ASIMTUFII, ABILIFY MAINTENA, ARISTADA, ERZOFRI, INVEGA HAFYERA, INVEGA SUSTENNA, INVEGA TRINZA, PERSERIS, RYKINDO, UZEDY, ZYPREXA RELPREVV
ANTI-REJECTION – Post-Transplant	MYHIBBIN oral solution, azasan, azathioprine, cyclosporine, everolimus, gengraf, mycophenolate mofetil, mycophenolate sodium, sirolimus, tacrolimus	ASTAGRAF XL, ENVARSUS XR, PROGRAF

The list is not all-inclusive and does not guarantee coverage. Please refer to your benefit plan documents provided by your employer or plan sponsor for benefit coverage and restrictions. This list is revised periodically and is subject to change without notice. Medications may be subject to prior authorization, step therapy requirements and quantity limits.

* = Specialty Drug (Tier 4)
lowercase = Generics; UPPERCASE = Brands
Preferred Alternatives = Generics (Tier 1) and Preferred Brands (Tier 2)
Non-Preferred Drugs = Non-Preferred Brands (Tier 3)

Major Drug Class Overview

Drug Class	Preferred Alternatives	Non-Preferred Drugs
ATTENTION-DEFICIT/ HYPERACTIVITY DISORDER (ADHD) – Non-Stimulants	atomoxetine, clonidine ER, guanfacine ER	ONYDA XR suspension, QELBREE
ATTENTION-DEFICIT/ HYPERACTIVITY DISORDER (ADHD) – Stimulants	AZSTARYS, amphet-dextroamphet 3-bead 24 HR ER, amphet-dextroamphet ER, dextroamphetamine IR solution, dexmethylphenidate ER, lisdexamfetamine (caps, chew), methylphenidate ER, methylphenidate IR (chew, patches, solution, caps, tabs), procentra solution, zenzedi	ADDERALL XR, ADZENYS XR-ODT, CONCERTA, COTEMPLA XR-ODT, DYANAVEL XR, JORNAY PM, QUILLICHEW ER, QUILLIVANT XR, VYVANSE, XELSTRYM PATCHES
CYSTIC FIBROSIS	KALYDECO*, PULMOZYME*, SYMDEKO*, TRIKAFTA*, albuterol, tobramycin nebulizer*	ARIKAYCE*, BETHKIS*, BRONCHITOL*, CAYSTON*, ORKAMBI*, TOBI PODHALER*
DERMATOLOGICALS – Acne & Rosacea Agents	DIFFERIN LOTION, ERY 2% PADS, ORACEA, SOOLANTRA, adapalene/benzoyl peroxide, adapalene, amnesteem, azelaic acid, benzepro, benzoyl peroxide/erythromycin, claravis, clindamycin/benzoyl peroxide, clindamycin/tretinoin, dapsone, doxycycline, erythromycin, isotretinoin, ivermectin cream, sulfacetamide, tazarotene, tretinoin, tretinoin microsphere, zenatane	ABSORICA LD, AKLIEF, ALTRENO, AMZEEQ, AZELEX, BENZEPRO, DIFFERIN CREAM AND GEL, DAZOMON, EPSOLAY, FINACEA FOAM, NORITATE, RETIN-A MICRO PUMP, RHOFADE, WINLEVI, ZILXI
DERMATOLOGICALS – Atopic Dermatitis (Eczema), Non-Steroidal	ADBRY*, CIBINQO*, DUPIXENT*, EBGLYSS*, RINVOQ*, pimecrolimus, tacrolimus	ADQUEY, ANZUPGO, EUCRISA, OPZELURA, ZORYVE

The list is not all-inclusive and does not guarantee coverage. Please refer to your benefit plan documents provided by your employer or plan sponsor for benefit coverage and restrictions. This list is revised periodically and is subject to change without notice. Medications may be subject to prior authorization, step therapy requirements and quantity limits.

* = Specialty Drug (Tier 4)
lowercase = Generics; UPPERCASE = Brands
Preferred Alternatives = Generics (Tier 1) and Preferred Brands (Tier 2)
Non-Preferred Drugs = Non-Preferred Brands (Tier 3)

Major Drug Class Overview

Drug Class	Preferred Alternatives	Non-Preferred Drugs
DERMATOLOGIALS – Psoriasis	COSENTYX*, HADLIMA*, HADLIMA PUSHTOUCH*, OTEZLA*, SELARSDI*, SIMLANDI*, SKYRIZI 150mg*, SOTYKTU*, STEQEYMA*, TAZORAC, YESINTEK*, XELJANZ* acitretin, anthralin, adalimumab-aaty*, adalimumab-adaz*, calcipotriene, calcitriol, tazarotene, tretinoin	BIMZELX*, HUMIRA*, ICOTYDE*, ILUMYA*, SILIQ*, SPEVIGO*, STELARA*, TALTZ*, VTAMA, ZITHRANOL, ZORYVE
DERMATOLOGIALS – Topical Corticosteroids	ENSTILAR, alclometasone, amcinonide, betamethasone, calcipotriene-betamethasone, clobetasol, clocortolone pivalate, desonide, desoximetasone, diflorasone, fluocinolone, fluocinonide, fluticasone, halcinonide, halobetasol, hydrocortisone, mometasone, triamcinolone	APEXICON E, BRYHALI, CHLOOXIA, DUOBRII, EPIFOAM, HALOG, IMPOYZ, NUCORT, PANDEL, PRAMOSONE, SERNIVO, ULTRAVATE, WYNZORA
DIABETIC SUPPLIES – Continuous Glucose Monitors (CGMs), Conventional Glucose Monitors, Insulin Pumps, Test Strips	CONTOUR NEXT, CONTOUR NEXT EZ, CONTOUR PLUS BLUE, DEXCOM G6 AND G7, FREESTYLE, FREESTYLE LIBRE 2 AND 3 PLUS, FREESTYLE LIBRE 14 DAY, iLet INSULIN PUMP, OMNIPOD 5 DEXG7G6, OMNIPOD 5 LIBRE2 PLUS, OMNIPOD CLASSIC PODS (GEN 3), OMNIPOD DASH, TWIIST INSULIN PUMP	ACCU-CHEK, EVERSENSE, GUARDIAN, MINIMED INSULIN PUMP, ONETOUCH ULTRA, ONETOUCH VERIO, PRECISION, T:SLIM INSULIN PUMP, TRUE METRIX, TRUE TRACK
DIABETIC SUPPLIES – Insulin Syringes, Ketone Test Strips, Lancets, Pen Needles	AUM MINI, BD, CARETOUCH, COMFORT TOUCH, CONTOUR NEXT, CONTOUR PLUS BLUE, DROPLET, KETO-DIASTIX, KETOSTIX, LEADER UNIFINE, MEDICHOICE, MEDLANCE PLUS, NOVOFINE, ONETOUCH ULTRA, ONETOUCH VERIO, PREFERRED PLUS, ULTILET, UNILET, UNIFINE **Generics-** CVS, H-E-B, Hy-Vee, Kroger, Meijer, ReliON (Walmart), Shopko, Wegmans, Walgreens	ABOUTTIME, ADVOCATE, AURORA, CAREFINE, COMFORT EZ, GENTEEL, GENTLE-LET, GNP ULTICARE, GNP ULTIGUARD, INSUPEN, LIFETOUCH, PHARMACIST CHOICE, PURE COMFORT, READYLANCE, SURE COMFORT, TRUE COMFORT, ULTICARE, ULTIGUARD, VERIFINE, VIVAGUARD

The list is not all-inclusive and does not guarantee coverage. Please refer to your benefit plan documents provided by your employer or plan sponsor for benefit coverage and restrictions. This list is revised periodically and is subject to change without notice. Medications may be subject to prior authorization, step therapy requirements and quantity limits.

* = Specialty Drug (Tier 4)
lowercase = Generics; UPPERCASE = Brands
Preferred Alternatives = Generics (Tier 1) and Preferred Brands (Tier 2)
Non-Preferred Drugs = Non-Preferred Brands (Tier 3)

Major Drug Class Overview

Drug Class	Preferred Alternatives	Non-Preferred Drugs
DIABETES – Short-Acting Insulin	FIASP, HUMALOG, HUMALOG MIX, HUMALOG TEMPO PEN, LYUMJEV, LYUMJEV TEMPO PEN, NOVOLOG, NOVOLOG MIX, insulin aspart, insulin lispro	ADMELOG, AFREZZA, APIDRA, KIRSTY, MERILOG, MYXREDLIN
DIABETES – Intermediate/Long-Acting Insulin	HUMULIN, LANTUS, LANTUS SOLOSTAR, LEVEMIR, NOVOLIN, REZVOGLAR, SEMGLEE-YFGN, TRESIBA, TOUJEO, insulin aspart pro & aspart, insulin degludec, insulin glargine, insulin glargine max solstar, insulin glargine-yfgn, insulin lispro prot & lispro	AWIQLI, BASAGLAR KWIKPEN, BASAGLAR TEMPO PEN
DIABETES – DPP-4 Inhibitors	JANUVIA, alogliptin, saxagliptin, sitagliptin	BRYNOVIN, TRADJENTA, ZITUVIO
DIABETES – GLP-1, GIP/GLP-1 Agonists	MOUNJARO, OZEMPIC, RYBELSUS, TRULICITY, exenatide, liraglutide	VICTOZA
DIABETES – SGLT2 Inhibitors	FARXIGA, JARDIANCE, bexagliflozin, dapagliflozin	BRENZAVVY, INVOKANA, STEGLATRO
DIABETES – Combination	GLYXAMBI, JANUMET, JANUMET XR, SOLIQUA, SYNJARDY, SYNJARDY XR, TRIJARDY XR, XIGDUO XR, XULTOPHY, alogliptin/metformin, alogliptin/pioglitazone, dapagliflozin/metformin ER, dapagliflozin/saxagliptin, saxagliptin/metformin ER, sitagliptin/metformin	INVOKAMET, INVOKAMET XR, KOMBIGLYZE XR, QTERN, SEGLUROMET, STEGLUJAN
ENDOCRINE – Testosterone Products	danazol, depo-testosterone, methyltestosterone, testosterone topical, testosterone cypionate, testosterone enanthate	AVEED, JATENZO, KYZATREX, METHITEST, NATESTO, TESTONE, TESTOPEL, TLANDO, UNDECATREX, XYOSTED

The list is not all-inclusive and does not guarantee coverage. Please refer to your benefit plan documents provided by your employer or plan sponsor for benefit coverage and restrictions. This list is revised periodically and is subject to change without notice. Medications may be subject to prior authorization, step therapy requirements and quantity limits.

* = Specialty Drug (Tier 4)
lowercase = Generics; UPPERCASE = Brands
Preferred Alternatives = Generics (Tier 1) and Preferred Brands (Tier 2)
Non-Preferred Drugs = Non-Preferred Brands (Tier 3)

Major Drug Class Overview

Drug Class	Preferred Alternatives	Non-Preferred Drugs
ENDOCRINE – Thyroid Products	ARMOUR THYROID, SYNTHROID, euthyrox, levo-T, levothyroxine, levoxyl, liothyronine, np thyroid, unithroid	ADTHYZA, ERMEZA, THYQUIDITY, TIROSINT, TIROSINT-SOL, TRIOSTAT
ESTROGEN/ ESTROGEN-FREE- Women's Health	CLIMARA PRO, DUAVEE, ESTRING, MYFEMBREE, ORIAHNN, PREMARIN TABLETS, PREMPHASE, PREMPRO, dotti patches, estradiol (patches, tablets, topical gel, pellet), estradiol valerate injection, est estrogens-methyltest, estradiol-norethindrone, fyavolv, jinteli, lyllana patches, mimvey, yuvafem	ANGELIQ, BIJUVA, COMBIPATCH, DEPO-ESTRADIOL, DIVIGEL, ELESTRIN, EVAMIST, FEMRING, IMVEXXY STARTER AND MAINTENANCE PACK, INTRAROSA, LYNKUET, MENEST, MENOSTAR, OSPHENA, PREFEST, PREMARIN VAG CREAM, VAGIFEM, VEOZAH
GASTROINTESTINAL – Chronic Idiopathic Constipation	TRULANCE, lubiprostone	LINZESS, MOTEGRITY
GASTROINTESTINAL – Crohn's Disease	ENTYVIO PEN*, HADLIMA*, RINVOQ*, SELARSDI*, SIMLANDI*, SKYRIZI 180mg, 360mg*, STEQEYMA*, YESINTEK* adalimumab-aaty*, adalimumab-adaz*, azathioprine, balsalazide, budesonide, mercaptopurine, methotrexate, mesalamine (capsules, enema, suppository, enteric coated tablets), prednisone, sulfasalazine	CIMZIA*, HUMIRA*, INFLECTRA*, RENFLEXIS*, SFROWASA, STELARA*, TYSABRI*, ZYMFENTRA*
GASTROINTESTINAL – Digestive Enzymes	CREON, ZENPEP	PANCREAZE, PERTZYE, SUCRAID, VIOKACE
GASTROINTESTINAL – Erosive Esophagitis, GERD	NEXIUM 2.5MG, 5MG oral suspension, dexlansoprazole, esomeprazole 40mg, lansoprazole 30mg, omeprazole 40mg, pantoprazole (oral suspension, tabs), rabeprazole	FIRST-PANTOPRAZOLE, FIRST-LANSOPRAZOLE, FIRST-OMEPRAZOLE, PRILOSEC ORAL PACKETS, VOQUEZNA

The list is not all-inclusive and does not guarantee coverage. Please refer to your benefit plan documents provided by your employer or plan sponsor for benefit coverage and restrictions. This list is revised periodically and is subject to change without notice. Medications may be subject to prior authorization, step therapy requirements and quantity limits.

* = Specialty Drug (Tier 4)
lowercase = Generics; UPPERCASE = Brands
Preferred Alternatives = Generics (Tier 1) and Preferred Brands (Tier 2)
Non-Preferred Drugs = Non-Preferred Brands (Tier 3)

Major Drug Class Overview

Drug Class	Preferred Alternatives	Non-Preferred Drugs
GASTROINTESTINAL – Irritable Bowel Syndrome	TRULANCE, VIBERZI, XIFAXAN 550MG alosetron, lubiprostone	IBSRELA, LINZESS, XIFAXAN 200MG*, ZELNORM *2oomg strength – FDA approved for traveler's diarrhea, not IBS
GASTROINTESTINAL – Opioid Induced Constipation	MOVANTIK, SYMPROIC, lubiprostone	RELISTOR
GASTROINTESTINAL – Ulcerative Colitis	ENTYVIO PEN*, HADLIMA*, OMVOH 100mg/ml*, RINVOQ*, SELARSDI*, SIMLANDI*, SKYRIZI 180mg*, 360mg*, STEQEYMA*, XELJANZ*, YESINTEK*, ZEPOSIA* adalimumab-aaty*, adalimumab-adaz*, azathioprine, balsalazide, budesonide, mercaptopurine, methotrexate, mesalamine (capsules, enema, suppository, enteric coated tablets), prednisone, sulfasalazine	DIPENTUM, HUMIRA*, INFLECTRA*, RENFLEXIS*, SFROWASA*, STELARA*, VELSIPITY*, ZYMFENTRA*
GROWTH HORMONES	GENOTROPIN*, GENOTROPIN MINIQUICK*, OMNITROPE*	HUMATROPE*, NGENLA*, NORDITROPIN FLEXPRO*, NUTROPIN AQ NUSPIN*, SAIZEN*, SKYTROFA*, SOGROYA*, ZOMACTON*
GOUT THERAPY	allopurinol, colchicine, colchicine-probenecid, febuxostat, probenecid	GLOPERBA, KRYSTEXXA*
HEART FAILURE	CORLANOR 5MG/5ML SOLUTION, ENTRESTO, FARXIGA, JARDIANCE, VERQUVO bisoprolol, carvedilol, eplerenone, ivabradine tablets, metoprolol succinate, sacubitril-valsartan, spironolactone	INPEFA

The list is not all-inclusive and does not guarantee coverage. Please refer to your benefit plan documents provided by your employer or plan sponsor for benefit coverage and restrictions. This list is revised periodically and is subject to change without notice. Medications may be subject to prior authorization, step therapy requirements and quantity limits.

* = Specialty Drug (Tier 4)
lowercase = Generics; UPPERCASE = Brands
Preferred Alternatives = Generics (Tier 1) and Preferred Brands (Tier 2)
Non-Preferred Drugs = Non-Preferred Brands (Tier 3)

Major Drug Class Overview

Drug Class	Preferred Alternatives	Non-Preferred Drugs
HEMATOPOIETIC AGENTS – Granulocyte Colony Stimulating Factors	FULPHILA*, FYLNETRA*, NIVESTYM*, ZARXIO*	FYLNETRA*, GRANIX*, NEULASTA*, NEULASTA ONPRO*, NEUPOGEN*, NYVEPRIA*, RELEUKO*, ROLVEDON*, STIMUFEND*, UDENYCA*, ZIEXTENZO*
HEPATITIS C	EPCLUSA*, HARVONI*, MAVYRET*, VOSEVI*, ledipasvir-sofosbuvir*, sofosbuvir-velpatasvir*	ZEPATIER*
HIGH CHOLESTEROL	NEXLIZET, REPATHA, REPATHA SURECLICK, REPATHA PUSHTRONEX SYSTEM, VASCEPA, atorvastatin, cholestyramine, colestipol, ezetimibe, ezetimibe/simvastatin, fenofibrate, fenofibric acid, icosapent ethyl, lovastatin, niacin ER, omega-3- acid ethyl esters, pravastatin, rosuvastatin, simvastatin	ALTOPREV, ATORVALIQ, EVKEEZA*, EZALLOR SPRINKLE, FLOLIPID, JUXTAPID*, LEROCHOL, LEQVIO, NEXLETOL, PRALUENT, ZYPITAMAG
HIV	APRETUDE, BIKTARVY, CIMDUO, DELSTRIGO, DESCOVY, DOVATO, EVOTAZ, GENVOYA, INTELENCE, ISENTRESS, ISENTRESS HD, JULUCA, NORVIR, ODEFSEY, PREZCOBIX, PREZISTA, STAVUDINE, SYMTUZA, TIVICAY, TIVICAY PD, TRIUMEQ, TRIUMEQ PD, VIREAD, efavirenz/emtricitabine/tenofovir, efavirenz/lamivudine/tenofovir, emtricitabine/tenofovir	APTIVUS, CABENUVA*, COMPLERA, EDURANT, EMTRIVA, FUZEON*, IDVYNSO, PIFELTRO, RETROVIR, REYATAZ, RUKOBIA, SELZENTRY, STRIBILD, SUNLENCA*, TROGARZO*, TYBOST, VIRACEPT, VOCABRIA, YEZTUGO

The list is not all-inclusive and does not guarantee coverage. Please refer to your benefit plan documents provided by your employer or plan sponsor for benefit coverage and restrictions. This list is revised periodically and is subject to change without notice. Medications may be subject to prior authorization, step therapy requirements and quantity limits.

* = Specialty Drug (Tier 4)
lowercase = Generics; UPPERCASE = Brands
Preferred Alternatives = Generics (Tier 1) and Preferred Brands (Tier 2)
Non-Preferred Drugs = Non-Preferred Brands (Tier 3)

Major Drug Class Overview

Drug Class	Preferred Alternatives	Non-Preferred Drugs
IMMUNOSUPPRESSANTS - Biologics, Biosimilars, Oral JAK Inhibitors, Non-Injectables	adalimumab-aaty*, adalimumab-adaz*, COSENTYX UNOREADY*, COSENTYX* SENSOREADY PEN, ENBREL*, ENTYVIO*, HADLIMA*, HADLIMA PUSHTOUCH*, OMVOH*, OTEZLA*, RINVOQ*, RINVOQ LQ*, SELARSDI*, SKYRIZI*, SIMLANDI*, SIMPONI 100MG*, SOTYKTU*, STEQEYMA*, TYENNE*, XELJANZ*, YESINTEK*	ABRILADA*, ACTEMRA*, ADALIMUMAB-AACF*, ADALIMUMAB-ADBM*, ADALIMUMAB-FKJP*, ADALIMUMAB-RYVK*, AMJEVITA*, BIMZELX*, CIMZIA*, CYLTEZO*, HULIO*, HUMIRA*, HYRIMOZ*, ICOTYDE*, IDACIO*, ILARIS*, ILUMYA*, INFLECTRA*, INFLIXIMAB*, KEVZARA*, KINERET*, OLUMIANT*, REMICADE*, RENFLEXIS*, SILIQ*, SIMPONI 50MG*, SIMPONI ARIA*, SPEVIGO*, STELARA*, TALTZ*, YUFLYMA*, YUSIMRY*, ZYMFENTRA*
INFERTILITY AGENTS	CLOMID, FOLLISTIM AQ*, OVIDREL*, PREGNYL*, cetrorelix acetate*, chorionic gonadotropin*, ganirelix acetate*	GONAL-F*, GONAL-F RFF*, MENOPUR*, NOVAREL*
MIGRAINES- CGRP Inhibitors	AIMOVIG, AJOVY, EMGALITY 120MG/ML, EMGALITY (300MG DOSE) 100MG/ML NURTEC, QULIPTA, UBRELVY	VYEPTI*, ZAVZPRET
MIGRAINES – Triptans/Non-Triptans (Oral)	REYVOW, almotriptan, eletriptan, ergotamine-caffeine, frovatriptan, naratriptan, propranolol, rizatriptan, sumatriptan, topiramate ER, zolmitriptan, zomig	ELYXYB, ERGOMAR, MIGERGOT
MIGRAINES – Triptans/Non-Triptans (Non-Oral)	dihydroergotamine mesylate (nasal, injection), sumatriptan nasal spray, sumatriptan succinate injection, zolmitriptan nasal spray	ONZETRA XSAIL, TOSYMRA, TRUDHESA, ZEMBRACE SYMTOUCH

The list is not all-inclusive and does not guarantee coverage. Please refer to your benefit plan documents provided by your employer or plan sponsor for benefit coverage and restrictions. This list is revised periodically and is subject to change without notice. Medications may be subject to prior authorization, step therapy requirements and quantity limits.

* = Specialty Drug (Tier 4)
lowercase = Generics; UPPERCASE = Brands
Preferred Alternatives = Generics (Tier 1) and Preferred Brands (Tier 2)
Non-Preferred Drugs = Non-Preferred Brands (Tier 3)

Major Drug Class Overview

Drug Class	Preferred Alternatives	Non-Preferred Drugs
MULTIPLE SCLEROSIS	AVONEX*, BETASERON*, KESIMPTA*, MAVENCLAD*, MAYZENT*, PLEGRIDY*, REBIF*, REBIF REBIDOSE*, VUMERITY*, ZEPOSIA* dalfampridine ER*, dimethyl fumarate*, fingolimod*, glatiramer acetate*, glatopa*, teriflunomide*	BAFIERTAM*, BRIUMVI*, EXTAVIA*, GILENYA 0.25MG CAPS*, LEMTRADA*, OCREVUS*, PONVORY*, TASCENSO ODT*, TYSABRI*
NEUROMUSCULAR BLOCKING AGENT – Botulinum Toxins	N/A	BOTOX*, BOTOX COSMETIC*, DYSPORT*, MYOBLOC*, XEOMIN*
OPHTHALMIC - Prostaglandins	LUMIGAN, bimatoprost, latanoprost, tafluprost (PF), travoprost (BAK Free)	DURYSTA, iDOSE*, IYUZEH, VYZULTA, XELPROS
OPHTHALMIC – Miscellaneous (Antibiotics/Steroids, Antihistamines, Dry Eye Syndrome, Non-Prostaglandins, Pain Relief, Steroids)	LOTEMAX, LOTEMAX SM, NATACYN, RESTASIS, SIMBRINZA, ZYLET, azelastine, brimonidine tartrate, brimonidine-dorzolamide, bromfenac, cyclosporine emulsion eye drops, dexamethasone, difluprednate, dorzolamide, fluorometholone, ketorolac, loteprednol etabonate, olopatadine, prednisolone acetate, prednisolone-bromfenac, tobramycin-dexamethasone	ACUVAIL, ALOCRIL, ALOMIDE, BESIVANCE, CEQUA, DEXTENZA, EYSUVIS, FML FORTE, ILEVRO, INVELTYS, IOPIDINE, KLARITY-L, LUMIFY, MAXIDEX, MIEBO, NEVANAC, PRED MILD, RESTASIS MULTIDOSE, RHOPRESSA, ROCKLATAN, TOBRADEX, TRYPTYR, UPNEEQ, VERKAZIA, VEVYE, VIZZ, XIIDRA, ZERVIATE
OSTEOPROSIS	BILDYOS*, ENOBY*, TYMLOS*, alendronate, calcitonin (salmon), etidronate sodium, ibandronate, risendronate, teriparatide (recombinant)*, zoledronic acid*	BINOSTO, BOSAYA*, CONEXXENCE*, EVENITY*, FOSAMAX PLUS D, JUBBONTI*, PROLIA*, XGEVA*

The list is not all-inclusive and does not guarantee coverage. Please refer to your benefit plan documents provided by your employer or plan sponsor for benefit coverage and restrictions. This list is revised periodically and is subject to change without notice. Medications may be subject to prior authorization, step therapy requirements and quantity limits.

* = Specialty Drug (Tier 4)
lowercase = Generics; UPPERCASE = Brands
Preferred Alternatives = Generics (Tier 1) and Preferred Brands (Tier 2)
Non-Preferred Drugs = Non-Preferred Brands (Tier 3)

Major Drug Class Overview

Drug Class	Preferred Alternatives	Non-Preferred Drugs
PULMONARY HYPERTENSION	OPSUMIT*, TRACLEER 32MG*, UPTRAVI*, ambrisentan*, bosentan*, sildenafil*, tadalafil*	ADCIRCA*, ADEMPAS*, FLOLAN*, LETAIRIS*, ORENITRAM*, REVATIO*, TRACLEER 62.5/125MG*, TADLIQ*, TYVASO*, VELETRI*, VENTAVIS*
RESPIRATORY – Asthma/COPD Anti-Cholinergics, Corticosteroids, Long-Acting Beta-Agonists, Short-Acting Beta-Agonists, Miscellaneous	AIRSUPRA, ARNUITY ELLIPTA, ASMANEX, ASMANEX TWISTHALER, ATROVENT HFA, INCRUSE ELLIPTA, QVAR REDIHALER, SEREVENT DISKUS, SPIRIVA RESPIMAT, VENTOLIN HFA, albuterol HFA, arformoterol tartrate, budesonide, cromolyn, fluticasone diskus, fluticasone furoate ellipta, fluticasone HFA, formoterol fumarate, ipratropium-albuterol, ipratropium HFA, levalbuterol HCl, montelukast, theophylline ER, tiotropium bromide, umeclidinium ellipta	ALVESCO, OHTUVAYRE, PROAIR DIGIHALER, PROAIR RESPICLICK, PULMICORT FLEXHALER, SPIRIVA HANDIHALER, STRIVERDI RESPIMAT, TUDORZA PRESSAIR, YUPELRI, ZYFLO
RESPIRATORY – Combination Products	ADVAIR HFA, ANORO ELLIPTA, BREO ELLIPTA, BREZTRI AEROSPHERE, COMBIVENT RESPIMAT, DULERA, STIOLTO RESPIMAT, SYMBICORT, TRELEGY ELLIPTA, budesonide-formoterol, fluticasone-salmeterol, fluticasone furoate-vilanterol, umeclidinium-vilanterol, wixela inhub	BEVESPI AEROSPHERE, DUAKLIR PRESSAIR
RESPIRATORY – Severe Asthma/COPD	DUPIXENT*, FASENRA **autoinjector***, NUCALA **autoinjector and syringe***, TEZSPIRE **autoinjector***, XOLAIR **autoinjector and syringe***	CINQAIR*, EXDENSUR*, FASENRA **syringe***, NUCALA **vial***, TEZSPIRE **syringe***, XOLAIR **vial***
RESPIRATORY SUPPLIES– Spacer/Holding Chambers	AEROCHAMBER, BREATHE EASE, BREATHERITE, COMPACT, EASIVENT, FLEXICHAMBER, INSPIREASE, OPTICHAMBER, PANDA MASK, PARI VORTEX, VORTEX	CLEVER CHOICE, EQ

The list is not all-inclusive and does not guarantee coverage. Please refer to your benefit plan documents provided by your employer or plan sponsor for benefit coverage and restrictions. This list is revised periodically and is subject to change without notice. Medications may be subject to prior authorization, step therapy requirements and quantity limits.

* = Specialty Drug (Tier 4)
lowercase = Generics; UPPERCASE = Brands
Preferred Alternatives = Generics (Tier 1) and Preferred Brands (Tier 2)
Non-Preferred Drugs = Non-Preferred Brands (Tier 3)

Major Drug Class Overview

Drug Class	Preferred Alternatives	Non-Preferred Drugs
SLEEP DISORDERS - Insomnia	BELSOMRA, estazolam, eszopiclone, temazepam, triazolam, zaleplon, zolpidem, zolpidem ER	EDLUAR, DAYVIGO, QUVIVIQ, SONATA, ZOLPIMIST
SLEEP DISORDERS - Narcolepsy	SUNOSI, armodafinil, dextroamphetamine, methylphenidate solution, methylphenidate IR tablets, methylphenidate ER (CD) capsules, modafinil, sodium oxybate*	LUMRYZ*, WAKIX*, XYREM*, XYWAV*
UROLOGICAL – Erectile Dysfunction	sildenafil, tadalafil, vardenafil	CAVERJECT, STENDRA
UROLOGICAL – Overactive Bladder	darifenacin, mirabegron ER, oxybutynin, solifenacin succinate, tolterodine tartrate, trospium chloride	GELNIQUE, GEMTESA, MYRBETRIQ SOLUTION, OXYTROL, VESICARE LS
WEIGHT LOSS	SAXENDA, WEGOVY, ZEPBOUND, benzphetamine, diethylpropion, orlistat, phendimetrazine, phentermine	CONTRAVE, FOUNDAYO, IMCIVREE*, LOMAIRA, PLENITY, QSYMIA

The list is not all-inclusive and does not guarantee coverage. Please refer to your benefit plan documents provided by your employer or plan sponsor for benefit coverage and restrictions. This list is revised periodically and is subject to change without notice. Medications may be subject to prior authorization, step therapy requirements and quantity limits.

* = Specialty Drug (Tier 4)
lowercase = Generics; UPPERCASE = Brands
Preferred Alternatives = Generics (Tier 1) and Preferred Brands (Tier 2)
Non-Preferred Drugs = Non-Preferred Brands (Tier 3)

Biosimilar Strategy Program

Biosimilar medications offer alternative treatment options for members prescribed high-cost specialty drugs. A biosimilar is similar to an FDA-approved biologic product and does not differ clinically from the reference product in safety and effectiveness. Below is a list of biosimilars and their preferred or non-preferred formulary status. Preferred means members are required to try and fail the preferred products before coverage is considered for a non-preferred option.

Humira and Adalimumab Biosimilar Coverage

Drug Class	Formulary Status	Available Strengths
adalimumab -aaty (unbranded Yuflyma)	Preferred; Specialty	20mg/0.2mL, 40mg/0.4mL, 80mg/0.8mL
adalimumab-adaz (unbranded Hyrimoz)	Preferred; Specialty	40mg/0.4mL
HADLIMA **HADLIMA PUSHTOUCH**	Preferred; Specialty	40mg/0.4mL, 40mg/0.8mL
SIMLANDI	Preferred; Specialty	40mg/0.4mL
ABRILADA **ADALIMUMAB-AACF** **ADALIMUMAB-ADBM** **ADALIMUMAB-BWWD** **ADALIMUMAB-FKJP** **ADALIMUMAB-RYVK** **AMJEVITA** **CYLTEZO** **HULIO** **HUMIRA** **HYRIMOZ** **IDACIO** **YUFLYMA** **YUSIMRY**	Non-Preferred; Specialty	10mg/0.1mL, 10mg/0.2mL, 20mg/0.2mL, 20mg/0.4mL, 40mg/0.4mL, 40mg/0.8mL, 80mg/0.8mL

The list is not all-inclusive and does not guarantee coverage. Please refer to your benefit plan documents provided by your employer or plan sponsor for benefit coverage and restrictions. This list is revised periodically and is subject to change without notice. Medications may be subject to prior authorization, step therapy requirements and quantity limits.

* = Specialty Drug (Tier 4)
lowercase = Generics; UPPERCASE = Brands
Preferred Alternatives = Generics (Tier 1) and Preferred Brands (Tier 2)
Non-Preferred Drugs = Non-Preferred Brands (Tier 3)

Actemra and Tocilzumab Biosimilar Coverage

Drug Class	Formulary Status	Available Strengths
TYENNE	Preferred; Specialty	162mg/0.9mL
ACTEMRA **AVOTZMA** **TOFIDENCE**	Non-Preferred; Specialty	162mg/0.9Ml, 80mg/4mL, 200mg/10mL, 400mg/20mL

Lantus and Insulin Glargine Biosimilar Coverage

Drug Class	Formulary Status	Available Strengths
insulin glargine-yfgn (unbranded Semglee-yfgn)	Preferred	100mg/ml
LANTUS	Preferred	100mg/ml
REZVOGLAR	Preferred	100mg/ml
SEMGLEE-YFGN	Preferred	100mg/ml
LANGLARA	Non-Preferred	100mg/ml

The list is not all-inclusive and does not guarantee coverage. Please refer to your benefit plan documents provided by your employer or plan sponsor for benefit coverage and restrictions. This list is revised periodically and is subject to change without notice. Medications may be subject to prior authorization, step therapy requirements and quantity limits.

* = Specialty Drug (Tier 4)
lowercase = Generics; UPPERCASE = Brands
Preferred Alternatives = Generics (Tier 1) and Preferred Brands (Tier 2)
Non-Preferred Drugs = Non-Preferred Brands (Tier 3)

Neulasta and Pegfilgrastim Biosimilar Coverage

Drug Class	Formulary Status	Available Strengths
FULPHILA	Preferred; Specialty	6mg/0.6mL
FYLNETRA	Preferred; Specialty	6mg/0.6mL
NEULASTA **NYVEPRIA** **STIMUFEND** **UDENYCA** **UDENYCA ONGO** **ZIEXTENZO**	Non-Preferred; Specialty	6mg/0.6mL

Neupogen and Filgrastim Biosimilar Coverage

Drug Class	Formulary Status	Available Strengths
NIVESTYM	Preferred; Specialty	300mcg/0.5mL 300mcg/mL 480mcg/0.8mL 480mcg/1.6mL
ZARXIO	Preferred; Specialty	300mcg/0.5mL 480mcg/0.8mL
GRANIX **NEUPOGEN** **NYPOZI** **RELEUKO**	Non-Preferred; Specialty	300mcg/0.5mL 300mcg/mL 480mcg/0.8mL 480mcg/1.6mL

The list is not all-inclusive and does not guarantee coverage. Please refer to your benefit plan documents provided by your employer or plan sponsor for benefit coverage and restrictions. This list is revised periodically and is subject to change without notice. Medications may be subject to prior authorization, step therapy requirements and quantity limits.

* = Specialty Drug (Tier 4)
lowercase = Generics; UPPERCASE = Brands
Preferred Alternatives = Generics (Tier 1) and Preferred Brands (Tier 2)
Non-Preferred Drugs = Non-Preferred Brands (Tier 3)

Prolia and Denosumab Biosimilar Coverage

Drug Class	Formulary Status	Available Strengths
BILDYOS **ENOBY**	Preferred; Specialty	60mg/mL
BOSAYA **CONEXXENCE** **JUBBONTI** **OSPOMYV** **PROLIA** **STOBOCLO**	Non-Preferred; Specialty	60mg/mL

Stelara and Ustekinumab Biosimilar Coverage

Drug Class	Formulary Status	Available Strengths
STEQEYMA	Preferred; Specialty	45mg/0.5mL, 90mg/mL
YESINTEK	Preferred; Specialty	45mg/0.5mL, 90mg/mL
IMULDOSA **OTULFI** **PYZCHIVA** **SELARSDI** **STELARA** **USTEKINUMAB** **USTEKINUMAB-AAUZ** **USTEKINUMAB-AEKN** **USTEKINUMAB-TTWE** **WEZLANA**	Non-Preferred; Specialty	45mg/0.5mL, 90mg/mL

The list is not all-inclusive and does not guarantee coverage. Please refer to your benefit plan documents provided by your employer or plan sponsor for benefit coverage and restrictions. This list is revised periodically and is subject to change without notice. Medications may be subject to prior authorization, step therapy requirements and quantity limits.

* = Specialty Drug (Tier 4)
lowercase = Generics; UPPERCASE = Brands
Preferred Alternatives = Generics (Tier 1) and Preferred Brands (Tier 2)
Non-Preferred Drugs = Non-Preferred Brands (Tier 3)